Galderma Doubles Forecast for Skin Drug
What happened
Dermatology firm Galderma has doubled its peak sales projection for its novel drug Nemluvio to over $4 billion. The revised forecast validates strong demand for new dermatology treatments and provided a boost to peers in the sector.
Why it matters
Nemluvio, known generically as nemolizumab, is a biologic therapy administered via subcutaneous injection. It is approved for treating moderate-to-severe atopic dermatitis and prurigo nodularis, two chronic skin conditions characterized by intense itching. The drug works by blocking the protein interleukin-31 (IL-31), which plays a key role in transmitting itch signals within the nervous system. The significant forecast revision is a result of Nemluvio's "outstanding launch trajectory," which brought in $452 million in sales in 2025. The company has noted that real-world use of the drug has exceeded initial expectations, particularly in providing rapid itch relief, a feature that physicians and patients prioritize. Galderma now anticipates the drug will reach financial break-even in 2026, a year ahead of its original schedule. The atopic dermatitis market is approximately ten times larger than the market for prurigo nodularis, representing a substantial growth area for Nemluvio. The drug competes with established treatments like Dupixent, but is seen as a strong option for its rapid impact on itch and a convenient every-eight-week maintenance dosing schedule. The success of Nemluvio contributed to a 50% year-over-year sales jump in Galderma's therapeutic dermatology unit, which reached $1.2 billion. This performance comes on the heels of the company's major initial public offering in March 2024, which was one of Europe's largest that year, raising approximately $2.6 billion.
Key numbers
- Dermatology firm Galderma has doubled its peak sales projection for its novel drug Nemluvio to over $4 billion.
- The drug works by blocking the protein interleukin-31 (IL-31), which plays a key role in transmitting itch signals within the nervous system.
- The significant forecast revision is a result of Nemluvio's "outstanding launch trajectory," which brought in $452 million in sales in 2025.
- Galderma now anticipates the drug will reach financial break-even in 2026, a year ahead of its original schedule.
What happens next
- The significant forecast revision is a result of Nemluvio's "outstanding launch trajectory," which brought in $452 million in sales in 2025.
- Galderma now anticipates the drug will reach financial break-even in 2026, a year ahead of its original schedule.
Quick answers
What happened in Galderma Doubles Forecast for Skin Drug?
Dermatology firm Galderma has doubled its peak sales projection for its novel drug Nemluvio to over $4 billion. The revised forecast validates strong demand for new dermatology treatments and provided a boost to peers in the sector.
Why does Galderma Doubles Forecast for Skin Drug matter?
Nemluvio, known generically as nemolizumab, is a biologic therapy administered via subcutaneous injection. It is approved for treating moderate-to-severe atopic dermatitis and prurigo nodularis, two chronic skin conditions characterized by intense itching. The drug works by blocking the protein interleukin-31 (IL-31), which plays a key role in transmitting itch signals within the nervous system. The significant forecast revision is a result of Nemluvio's "outstanding launch trajectory," which brought in $452 million in sales in 2025. The company has noted that real-world use of the drug has exceeded initial expectations, particularly in providing rapid itch relief, a feature that physicians and patients prioritize. Galderma now anticipates the drug will reach financial break-even in 2026, a year ahead of its original schedule. The atopic dermatitis market is approximately ten times larger than the market for prurigo nodularis, representing a substantial growth area for Nemluvio. The drug competes with established treatments like Dupixent, but is seen as a strong option for its rapid impact on itch and a convenient every-eight-week maintenance dosing schedule. The success of Nemluvio contributed to a 50% year-over-year sales jump in Galderma's therapeutic dermatology unit, which reached $1.2 billion. This performance comes on the heels of the company's major initial public offering in March 2024, which was one of Europe's largest that year, raising approximately $2.6 billion.
